The Clinicopathologic Features and Prognostic Impact of ALK Positivity in Patients with Resected Gastric Cancer

Annals of Surgical Oncology

Volumn 22, Issue 12, 2015, Pages 3938-3945

  Chon, Hong Jae ^a,b   Kim, Hye Ryun ^a,b   Shin, Eunah ^c   Kim, Chan ^a,b   Heo, Su Jin ^a   Lee, Choong kun ^a   Park, Jin Kyu ^c   Noh, Sung Hoon ^a   Chung, Hyun Cheol ^a,b   Rha, Sun Young ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c CFC Pathology Laboratory   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; PROTEIN TYROSINE KINASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CELL COMPONENT; CLINICAL FEATURE; DISEASE FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GASTRECTOMY; GENE REARRANGEMENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PROTEIN EXPRESSION; RECURRENCE RISK; SIGNET RING CARCINOMA; STOMACH CANCER; TISSUE SECTION; ADENOCARCINOMA; AGE; CANCER GRADING; CANCER STAGING; CHEMISTRY; GASTROESOPHAGEAL JUNCTION; GENETICS; MIDDLE AGED; PATHOLOGY; STOMACH TUMOR; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; ESOPHAGOGASTRIC JUNCTION; FEMALE; GASTRECTOMY; GENE REARRANGEMENT; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; SURVIVAL RATE; YOUNG ADULT;

EID: 84943347947     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-015-4376-8     Document Type: Article

References (27)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: Cancer J Clin. 2011;61:69–90.
2. Bang Y-J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.
3. Lennerz JK, Kwak EL, Ackerman A, et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 2011;29:4803–10.
4. Deng N, Goh LK, Wang H, et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut. 2012;61:673–84.
5. Wu K, Nie Y, Guo C, Chen Y, Ding J, Fan D. Molecular basis of therapeutic approaches to gastric cancer. J Gastroenterol Hepatol. 2009;24:37–41.
6. Lauren P. The two histological main types of gastric carcinoma: an attempt at a histoclinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.
7. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA. 1991;265:1287–9.
8. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12:354.
9. Tay ST, Leong SH, Yu K, et al. A combined comparative genomic hybridization and expression microarray analysis of gastric cancer reveals novel molecular subtypes. Cancer Res. 2003;63:3309–16.
10. Ooi CH, Ivanova T, Wu J, et al. Oncogenic pathway combinations predict clinical prognosis in gastric cancer. PLoS Genet. 2009;5:e1000676.
11. Shah MA, Khanin R, Tang L, et al. Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res. 2011;17:2693–701.
12. Tanner M, Hollmen M, Junttila T, et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005;16:273–8.
13. Albarello L, Pecciarini L, Doglioni C. HER2 testing in gastric cancer. Adv Anat Pathol. 2011;18:53–9.
14. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4–ALK fusion gene in non–small cell lung cancer. Nature. 2007;448:561–6.
15. Horn L, Pao W. EML4-ALK: Honing in on a new target in non–small cell lung cancer. J Clin Oncol. 2009;27:4232–5.
16. Kwak EL, Bang Y-J, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer. N Engl J Med. 2010;363:1693–703.
17. Lin E, Li L, Guan Y, et al. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non–small cell lung cancers. Mol Cancer Res. 2009;7:1466–76.
18. Sugawara E, Togashi Y, Kuroda N, et al. Identification of anaplastic lymphoma kinase fusions in renal cancer. Cancer. 2012;118:4427–36.
19. Murugan AK, Xing M. Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. Cancer Res. 2011;71:4403–11.
20. van Gaal JC, Flucke UE, Roeffen MH, et al. Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications. J Clin Oncol. 2012;30:308–15.
21. Siewert J, Stein H. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998;85:1457–9.
22. Park HS, Lee JK, Kim D-W, et al. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Lung Cancer. 2012;77:288–92.
23. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non–small cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27:4247–53.
24. Sandlund JT, Pui C, Roberts W, et al. Clinicopathologic features and treatment outcome of children with large-cell lymphoma and the t(2; 5)(p23; q35). Blood. 1994;84:2467–71.
25. Coffin CM, Patel A, Perkins S, Elenitoba-Johnson KS, Perlman E, Griffin CA. ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Mod Pathol. 2001;14:569–76.
26. Webb TR, Slavish J, George RE, et al. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther. 2009;9:331–56.
27. Doebele RC, Lu X, Sumey C, et al. Oncogene status predicts patterns of metastatic spread in treatment-naive non-small cell lung cancer. Cancer. 2012;118:4502–11.